Nine-year Phase 3 CLL14 results presented at EHA 2026 show fixed-duration venetoclax plus obinutuzumab delivered a median 7.6 years before next treatment and significantly improved progression-free survival in frontline CLL.
Written By: Shaik Yasmeen, PharmD
Reviewed By: Pharmacally Editorial Team
Nine-year follow-up data from the Phase 3 CLL14 trial(NCT02242942)showed that one year of fixed-duration venetoclax plus obinutuzumab delivered durable disease control and a median 7.6 years before next treatment in previously untreated chronic lymphocytic leukemia (CLL), reinforcing the long-term value of time-limited targeted therapy.
Presented at the European Hematology Association (EHA) 2026 Congress, the study was conducted by the German CLL Study Group in collaboration with AbbVie and compared venetoclax plus obinutuzumab against obinutuzumab plus chlorambucil in previously untreated patients with coexisting medical conditions.
Trial Design and Patient Population
The randomized, multicenter, open-label trial enrolled 432 patients with untreated CLL and significant comorbidity burden or impaired renal function. Participants received either venetoclax plus obinutuzumab (n=216) or chlorambucil plus obinutuzumab (n=216). Venetoclax was administered for a fixed duration of 12 months alongside six cycles of obinutuzumab.
Sustained Efficacy Over Nine Years
After a median follow-up of 9.2 years, venetoclax plus obinutuzumab maintained a significant progression-free survival (PFS) advantage over the chlorambucil-based regimen in this population of previously untreated patients with coexisting medical conditions. Median PFS reached 6.4 years versus 3.2 years (HR 0.50; 95% CI, 0.39–0.63; p<0.001).
Importantly, patients receiving the venetoclax combination achieved a median time to next treatment (TTNT) of 7.6 years, underscoring the durability of disease control after completion of fixed-duration therapy and allowing many patients to remain free from additional CLL-directed treatment for nearly eight years.
Minimal Residual Disease and Long-Term Disease Control
Investigators highlighted that deep minimal residual disease (MRD) responses observed early in treatment translated into durable long-term disease control. The sustained separation of PFS curves and prolonged TTNT support the long-lasting clinical benefit achieved with the fixed-duration venetoclax-based regimen.
Manageable Long-Term Safety Profile
The safety profile remained consistent with earlier reports. The most common Grade ≥3 adverse events included neutropenia, thrombocytopenia, infusion-related reactions, anemia, febrile neutropenia, pneumonia, and leukopenia. No new long-term safety signals emerged, supporting the regimen’s tolerability in patients with coexisting medical conditions.
Clinical Implications
Daejin Abidoye of AbbVie said the nine-year results further strengthen the evidence supporting venetoclax-based combinations in frontline CLL, highlighting the potential for prolonged disease control after one year of fixed-duration therapy.
Kirsten Fischer, M.D., of University Hospital Cologne said the findings reinforce the durable benefit of venetoclax plus obinutuzumab, with patients remaining free from subsequent CLL treatment for a median of nearly eight years.
Strategic Impact on Frontline CLL Therapy
Venetoclax is a selective BCL-2 inhibitor that restores apoptosis in malignant B cells. Combined with the anti-CD20 antibody obinutuzumab, it established one of the first fixed-duration targeted treatment approaches in CLL.
The final CLL14 analysis adds some of the longest follow-up data available for a fixed-duration targeted regimen in frontline CLL. The findings support the long-term clinical value of stopping therapy after a defined treatment period while maintaining durable disease control for years afterward.
Global Availability
Venetoclax, marketed as VENCLYXTO outside the United States, is jointly developed by AbbVie and Roche and is approved in more than 80 countries. The latest findings add to a growing body of long-term evidence supporting fixed-duration venetoclax regimens and are expected to continue shaping frontline treatment strategies for patients with CLL and coexisting medical conditions.
Reference
About the Writer
Shaik Yasmeen (LinkedIn) is a Pharm.D graduate with interests in clinical pharmacy, pharmacovigilance, and medical writing. She has gained experience through hospital clinical postings, patient case reviews, case presentations, and literature evaluation. Passionate about evidence-based healthcare, she is committed to creating accurate and engaging medical content while continuously expanding her professional knowledge.